Treatment of refractory myasthenia: "Rebooting" with high-dose cyclophosphamide

Annals of Neurology

Volumn 53, Issue 1, 2003, Pages 29-34

  Drachman, Daniel B ^a   Jones, Richard J ^b   Brodsky, Robert A ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MESNA; MYCOPHENOLIC ACID; ONDANSETRON; PREDNISOLONE; PYRIDOSTIGMINE;

ADULT; ALOPECIA; AMENORRHEA; ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CLINICAL EXAMINATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKOPENIA; MALE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NAUSEA; NEUTROPENIA; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; REFRACTORY MYASTHENIA GRAVIS; REMISSION; SYMPTOM; THROMBOCYTOPENIA; THYMECTOMY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037235889     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10400     Document Type: Article

References (35)

1. Drachman DB. Myasthenia gravis. In: Rose N, Mackay IR, eds. The autoimmune diseases. San Diego: Academic Press, 1998:637-662.
2. Drachman DB. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve 1996;19:1239-1251.
3. Chaudhry VV, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96.
4. Newsom-Davis J, Vincent A, Wilson SG, et al. [Plasmapheresis for myasthenia gravis]. N Engl J Med 1978;298:456-457.
5. Keesey J, Buffkin D, Kebo D, et al. Plasma exchange alone as therapy for myasthenia gravis. Ann N Y Acad Sci 1981;377:729-743.
6. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-796.
7. Pestronk A, Drachman DB, Adams RN. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve 1982;5:79-84.
8. Pestronk A, Drachman DB, Teoh R, Adams RN. Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neurol 1983;14:235-241.
9. Marmont AM, Van Bekkum DW. Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. Bone Marrow Transplant 1995;16:497-498.
10. Burt RK, Traynor A, Burns W. Hematopoietic stem cell transplantation of multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Cancer Treat Res 1999;101:157-184.
11. Burt RK. Immune ablation and hematopoietic stem cell rescue for severe autoimmune diseases (SADS). Cancer Treat Res 1997;77:317-332.
12. Comi G, Kappos L, Clanet M, et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J Neurol 2000;247:376-382.
13. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol 1998;99:116-132.
14. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002;99:1943-1951.
15. Barnes RA, Stallard N. Severe infections after bone marrow transplantation. Curr Opin Crit Care 2001;7:362-366.
16. Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996;88:3621-3625.
17. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997;99:9-22.
18. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996;87:491-494.
19. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998;129:1031-1035.
20. Brodsky RA, Petri M, Jones RJ. Hematopoietic stem cell transplantation for systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:377-387.
21. Moyo V, Smith B, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002;100:704-706.
22. Gordon MY, Goldman JM, Gordon-Smith EC. 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 1985;9:1017-1021.
23. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85:2742-2746.
24. Drachman DB. Myasthenia gravis: successful treatment in the 21st century. Immunosuppressive treatment of neuromuscular diseases. American Academy of Neurology Course: # 2002.
25. Vial T, Chauplannaz G, Brunel P, et al. [Exacerbation of myasthenia gravis by pefloxacin]. Rev Neurol (Paris) 1995;151:286-287.
26. Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol 2001;66:71.
27. Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001;135:477-483.
28. Nousari HC, Brodsky RA, Jones RJ, et al. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999;40:750-754.
29. Dowell JE, Moots PL, Stein RS. Myasthenia gravis after allogeneic bone marrow transplantation for lymphoblastic lymphoma. Bone Marrow Transplant 1999;24:1359-1361.
30. Tse S, Saunders EF, Silverman E, et al. Myasthenia gravis and polymyositis as manifestations of chronic graft- versus-host-disease. Bone Marrow Transplant 1999;23:397-399.
31. Yanagihara C, Nakaji K, Tanaka Y, et al. [A patient of chronic graft-versus-host disease presenting simultaneously with polymyositis and myasthenia gravis]. Rinsho Shinkeigaku 2001;41:503-506.
32. Brodsky RA, Jones RJ. High-dose cyclophosphamide in aplastic anaemia. Lancet 2001;357:1128-1129.
33. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. Philadelphia: Saunders, 1997.
34. Poussier P, Julius M. Thymus independent T cell development and selection in the intestinal epithelium. Annu Rev Immunol 1994;12:521-553.
35. Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.